Allison, Michael

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity

Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. (1996) · Science

Complement system in diseasesImmunotherapy and Immune Responses

Cited by 1,197

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 623

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 499

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 497

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 479

Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease

Azzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 369

Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease

Aravinthan, A., Scarpini, C., Tachtatzis, P., Verma, S., Penrhyn-Lowe, S., Harvey, R., Davies, S. E., Allison, M., Coleman, N., & Alexander, G. (2013) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentTelomeres, Telomerase, and Senescence

Cited by 326

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

Petroff, D., Blank, V., Newsome, P. N., Shalimar, Voican, C. S., Thiele, M., de Lédinghen, V., Baumeler, S., Chan, W. K., Perlemuter, G., et al. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 268

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 262

Risk factors for recurrent primary sclerosing cholangitis after liver transplantation

Ravikumar, R., Tsochatzis, E., Jose, S., Allison, M., Athale, A., Creamer, F., Gunson, B., Iyer, V., Madanur, M., Manas, D., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityOrgan Transplantation Techniques and Outcomes

Cited by 173

Acquisition of epithelial plasticity in human chronic liver disease

Gribben, C., Galanakis, V., Calderwood, A., Williams, E. C., Chazarra-Gil, R., Larraz, M., Frau, C., Puengel, T., Guillot, A., Rouhani, F. J., et al. (2024) · Nature

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 142

Hepatocyte Expression of the Senescence Marker p21 Is Linked to Fibrosis and an Adverse Liver-Related Outcome in Alcohol-Related Liver Disease

Aravinthan, A., Pietrosi, G., Hoare, M., Jupp, J., Marshall, A., Verrill, C., Davies, S., Bateman, A., Sheron, N., Allison, M., et al. (2013) · PLoS ONE

Alcohol Consumption and Health EffectsLiver physiology and pathology

Cited by 117

Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption

Sanders, F. W. B., Acharjee, A., Walker, C., Marney, L., Roberts, L. D., Imamura, F., Jenkins, B., Case, J., Ray, S., Virtue, S., et al. (2018) · Genome Biology

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 114

Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis

Vacca, M., Leslie, J., Virtue, S., Lam, B. Y. H., Govaere, O., Tiniakos, D., Snow, S., Davies, S., Petkevicius, K., Tong, Z., et al. (2020) · Nature Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 60

Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression

Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism

Liver Disease Diagnosis and TreatmentCancer, Lipids, and Metabolism

Cited by 52

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 28